Innovations in Primary Liver Cancer
Book your seat today!

Special registration rates for trainees, residents and ILCA Members!

Register Now!


ILCA is very pleased to announce that the next edition of the ILCA School of Liver Cancer will be virtual this December 2020.

The ILCA School provides fellows in gastroenterology, hepatology, basics/transitional researchers and other liver cancer-related professionals an opportunity to enhance their scientific experience by attending a multidisciplinary programme delivered by the most eminent international liver cancer specialists.

Sign today and join to get the deepest knowledge on:

  • Understanding the pathogenesis of hepatocellular carcinoma and how to translate this knowledge in clinical practice
  • Knowing the effect of antiviral treatment on the natural history of HCC
  • Understanding the place of curative treatments (transplantation, resection and ablation) in management of early HCC
  • Describing how radiology could help for the diagnosis and the assessment of the radiological response of HCC
  • Defining the role of pathology in HCC management
  • Discussing  the evidence about SIRT and tyrosine kinase inhibitors in advanced HCC



Friday 11th December 2020

Opening Remarks

08:25-08:30: Jean-Charles Nault (Avicenne Hospital, Bobigny, APHP, Cordeliers research center, Paris), Eric Vibert (Paul Brousse hospital, Villejuif, APHP)

The Hepatocellular Carcinoma Session
Risk factors, screening and diagnosis of HCC: What is new?

08:30-08:45: Perspective on epidemiology and HCC screening in the era of NASH -Nathalie Ganne-Carrie (Avicenne Hospital, Bobigny, APHP, Cordeliers research centre, Paris)

08:45-09:00: Understanding the physiopathology of NASH related HCC – Mathias Heikenwalder (Heidelberg, DKFZ)

09:00-09:15: Update on the Imaging Diagnosis of HCC – Alain Luciani (Mondor Hospital, Créteil, APHP)

09:15-09:30: The future of HCC pathology – Julien Calderaro (Mondor Hospital, Créteil, APHP)

09:30-10:00: Blast session on hot topic: controversies in HCC screening and diagnosis

  • Impact of antiviral treatment on tumor occurrence and recurrence – Pierre Nahon (Avicenne Hospital, Bobigny, APHP, Cordeliers research centre, Paris
  • Why and how to assess non-tumor liver in HCC patients ? – François Durand (Beaujon Hospital, Clichy, APHP)

10:00-10:30 Virtual Coffee break

Early HCC: can we go beyond guidelines?

10:30-10:45: Preclinical models of HCC and prediction of therapeutic response – Sandra Rebouissou (Cordeliers research centre, Paris)

10:45-11:00: Why and how to expend criteria for surgery? – Eric Vibert (Paul Brousse Hospital, Villejuif, APHP)

11:00-11:15: Current knowledge and innovation in percutaneous treatment of HCC – Olivier Seror (Avicenne Hospital, Bobigny, APHP, Cordeliers research centre, Paris)

11:15-11:30: Blast session on hot topic: can we improve treatment of early HCC?

  • The place of mini-invasive surgery: short term advantages and bridge to liver transplantation – Olivier Scatton (Pitié-Salpétrière Hospital, Paris, APHP)
  • Can we expend criteria of liver transplantation beyond composite criteria ? – Christophe Duvoux (Mondor Hospital, Créteil, APHP)

Discover the full programme here

What to expect at ILCA School Paris

ILCA 2020 Virtual Conference

All ILCA 2020 Virtual Conference content, along with the industry symposia, will be available for up to 12 months to all registered participants on the digital platform.

Navigate through the scientific resources, presentations, Q&A sessions, e-poster presentations and more.

Download the ILCA mobile and desktop app